Evidence map›Paper›PMID 41607197›Full record

ArticleACS chemical neuroscience2026

Multitargeted Aza-Arylcarboxamides for Neurodegenerative Diseases: Potent Histamine H

Flavia B Lopes, Tobias Werner, Izilda A Bagatin, Holger Stark, João Paulo S Fernandes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Flavia B LopesDepartment of Pharmaceutical Sciences, Federal University of São Paulo, Diadema 09913-030, Brazil.
Tobias WernerInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Duesseldorf 40225, Germany.
Izilda A BagatinDepartment of Chemistry, Federal University of São Paulo, Diadema 09972-270, Brazil.ORCID 0000-0002-3957-2730
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Duesseldorf 40225, Germany.ORCID 0000-0003-3336-1710
João Paulo S FernandesDepartment of Pharmaceutical Sciences, Federal University of São Paulo, Diadema 09913-030, Brazil.ORCID 0000-0002-9089-273X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases are conditions characterized by neuronal loss in the nervous system, leading to diverse symptoms associated with complex pathological mechanisms. Dysregulation of metal ions such as iron and copper is linked to oxidative stress and consequently contributes to neuronal toxicity. Considering this, multitarget agents represent promising therapeutic strategies for the treatment of neurodegenerative disorders. In this study, a series of 24 novel multitarget compounds were designed to interact with histamine H

Indexed as

Chelating AgentsCholinesterase InhibitorsNeurodegenerative DiseasesReceptors, Histamine H3AcetylcholinesteraseAnimalsButyrylcholinesteraseHumansLigandsStructure-Activity RelationshipAcetylcholinesteraseButyrylcholinesteraseChelating AgentsCholinesterase InhibitorsLigandsReceptors, Histamine H3cholinesterase inhibitorhistamine H3 receptormetal chelating compoundmultitargetingneurodegenerative disease

Identifiers

PMID41607197
PMCPMC12964414

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.